|
2024-02-09 |
2024-02-07 |
B
Purchase
|
Scopa James Paul
Non-Executive Director
|
100,000
+inf%
1.35
135,000
USD
|
100,000
+inf%
|
1.35
|
135,000
USD
|
|
|
2024-02-09 |
2024-02-07 |
B
Purchase
|
Lupher, Jr. Mark L.
Non-Executive Director
|
130,000
+inf%
1.35
175,500
USD
|
130,000
+inf%
|
1.35
|
175,500
USD
|
|
|
2023-09-18 |
2023-09-15 |
S
Sale
|
Seyedkazemi Setareh
Chief Development Officer
Officer
|
130
-0.3%
1.55
201
USD
|
130
-0.3%
|
1.55
|
201
USD
|
|
|
2023-09-18 |
2023-09-15 |
PS
Planned sale
|
Seyedkazemi Setareh
Chief Development Officer
Officer
|
6,071
-11.3%
1.52
9,228
USD
|
6,071
-11.3%
|
1.52
|
9,228
USD
|
|
|
2023-06-09 |
2023-06-07 |
B
Purchase
|
Rubinstein Linda M
Chief Financial Officer
Officer
|
100,000
+inf%
1.45
145,490
USD
|
100,000
+inf%
|
1.45
|
145,490
USD
|
|
|
2023-03-17 |
2023-03-15 |
PS
Planned sale
|
Soparkar Peter
Chief Operating Officer
Officer
|
13,360
-4.8%
0.78
10,442
USD
|
13,360
-4.8%
|
0.78
|
10,442
USD
|
|
|
2023-03-17 |
2023-03-15 |
PS
Planned sale
|
Fischer Laurent
CEO, President and Director
Executive Director
|
41,239
-5.6%
0.78
32,232
USD
|
41,239
-5.6%
|
0.78
|
32,232
USD
|
|
|
2023-03-17 |
2023-03-15 |
PS
Planned sale
|
Riley Brigit
Chief Scientific Officer
Officer
|
7,299
-5.9%
0.78
5,705
USD
|
7,299
-5.9%
|
0.78
|
5,705
USD
|
|
|
2022-09-21 |
2022-09-19 |
PS
Planned sale
|
Fischer Laurent
CEO, President and Director
Executive Director
|
41,082
-5.3%
1.07
43,941
USD
|
41,082
-5.3%
|
1.07
|
43,941
USD
|
|
|
2022-09-21 |
2022-09-19 |
PS
Planned sale
|
Soparkar Peter
See Remarks section
Officer
|
13,305
-4.6%
1.07
14,232
USD
|
13,305
-4.6%
|
1.07
|
14,232
USD
|
|
|
2022-09-21 |
2022-09-19 |
PS
Planned sale
|
Riley Brigit
Chief Scientific Officer
Officer
|
7,266
-5.8%
1.07
7,772
USD
|
7,266
-5.8%
|
1.07
|
7,772
USD
|
|
|
2022-09-21 |
2022-09-19 |
S
Sale
|
Seyedkazemi Setareh
Chief Development Officer
Officer
|
6,058
-11.2%
1.07
6,480
USD
|
6,058
-11.2%
|
1.07
|
6,480
USD
|
|
|
2022-09-21 |
2022-09-19 |
S
Sale
|
Beckman Richard
Chief Medical Officer
Officer
|
4,272
-9.9%
1.07
4,570
USD
|
4,272
-9.9%
|
1.07
|
4,570
USD
|
|
|
2022-05-24 |
2022-05-23 |
B
Purchase
|
Seyedkazemi Setareh
Chief Development Officer
Officer
|
20,000
+3333.3%
0.84
16,800
USD
|
20,000
+3333.3%
|
0.84
|
16,800
USD
|
|
|
2022-05-19 |
2022-05-17 |
B
Purchase
|
Beckman Richard
Chief Medical Officer
Officer
|
10,000
+inf%
0.82
8,228
USD
|
10,000
+inf%
|
0.82
|
8,228
USD
|
|
|
2022-05-17 |
2022-05-17 |
B
Purchase
|
D'Souza Rupert
Chief Financial Officer
Officer
|
10,000
+92.2%
0.83
8,272
USD
|
10,000
+92.2%
|
0.83
|
8,272
USD
|
|
|
2022-05-18 |
2022-05-16 |
B
Purchase
|
Svoronos Dawn
Non-Executive Director
|
30,000
+150.0%
0.85
25,578
USD
|
30,000
+150.0%
|
0.85
|
25,578
USD
|
|
|
2022-05-17 |
2022-05-13 |
B
Purchase
|
D'Souza Rupert
Chief Financial Officer
Officer
|
10,000
+1176.5%
0.86
8,585
USD
|
10,000
+1176.5%
|
0.86
|
8,585
USD
|
|
|
2022-04-22 |
2022-04-20 |
B
Purchase
|
Fischer Laurent
CEO, President and Director
Executive Director
|
25,000
+3.4%
1.11
27,800
USD
|
25,000
+3.4%
|
1.11
|
27,800
USD
|
|
|
2022-04-20 |
2022-04-19 |
B
Purchase
|
Soparkar Peter
See Remarks section
Officer
|
21,750
+8.4%
1.14
24,795
USD
|
21,750
+8.4%
|
1.14
|
24,795
USD
|
|
|
2022-04-20 |
2022-04-19 |
B
Purchase
|
Soparkar Peter
See Remarks section
Officer
|
175
+0.1%
1.14
199
USD
|
175
+0.1%
|
1.14
|
199
USD
|
|
|
2021-12-10 |
2021-12-09 |
B
Purchase
|
Fischer Laurent
CEO, President and Director
Executive Director
|
14,323
+2.0%
1.85
26,498
USD
|
14,323
+2.0%
|
1.85
|
26,498
USD
|
|
|
2021-12-10 |
2021-12-08 |
PP
Planned purchase
|
Fischer Laurent
CEO, President and Director
Executive Director
|
10,677
+1.5%
1.79
19,112
USD
|
10,677
+1.5%
|
1.79
|
19,112
USD
|
|
|
2021-12-10 |
2021-12-08 |
PP
Planned purchase
|
Soparkar Peter
See Remarks section
Officer
|
25,000
+10.7%
1.91
47,750
USD
|
25,000
+10.7%
|
1.91
|
47,750
USD
|
|
|
2021-11-17 |
2021-11-15 |
S
Sale
|
Scopa James Paul
Non-Executive Director
|
50,000
-93.7%
2.18
109,000
USD
|
50,000
-93.7%
|
2.18
|
109,000
USD
|
|
|
2021-10-04 |
2021-09-30 |
S
Sale
|
Clark Julie
Chief Medical Officer
Officer
|
4,766
-2.8%
2.17
10,342
USD
|
4,766
-2.8%
|
2.17
|
10,342
USD
|
|
|
2021-04-01 |
2021-03-31 |
B
Purchase
|
Svoronos Dawn
Non-Executive Director
|
20,000
+inf%
10.02
200,338
USD
|
20,000
+inf%
|
10.02
|
200,338
USD
|
|
|
2021-03-24 |
2021-03-24 |
B
Purchase
|
Machado Patrick
Non-Executive Director
|
10,000
+12.8%
9.92
99,196
USD
|
10,000
+12.8%
|
9.92
|
99,196
USD
|
|
|
2021-03-24 |
2021-03-24 |
B
Purchase
|
Fischer Laurent
CEO and Director
Executive Director
|
10,000
+61.4%
9.88
98,780
USD
|
10,000
+61.4%
|
9.88
|
98,780
USD
|
|
|
2021-02-11 |
2021-02-09 |
S
Sale
|
PATTERSON LEONE D
President and CFO
Officer
|
62
-0.1%
14.14
877
USD
|
62
-0.1%
|
14.14
|
877
USD
|
|
|
2021-02-11 |
2021-02-09 |
S
Sale
|
PATTERSON LEONE D
President and CFO
Officer
|
12,471
-11.3%
14.10
175,841
USD
|
12,471
-11.3%
|
14.10
|
175,841
USD
|
|
|
2021-01-19 |
2021-01-15 |
B
Purchase
|
Machado Patrick
Non-Executive Director
|
10,000
+14.7%
11.52
115,174
USD
|
10,000
+14.7%
|
11.52
|
115,174
USD
|
|
|
2021-01-19 |
2021-01-15 |
B
Purchase
|
Fischer Laurent
CEO and Director
Executive Director
|
8,600
+111.8%
11.53
99,191
USD
|
8,600
+111.8%
|
11.53
|
99,191
USD
|
|
|
2020-08-19 |
2020-08-17 |
PP
Planned purchase
|
Soparkar Peter
Chief Legal Officer
Officer
|
7,692
+256.4%
13.00
99,996
USD
|
7,692
+256.4%
|
13.00
|
99,996
USD
|
|
|
2020-08-19 |
2020-08-17 |
B
Purchase
|
Fischer Laurent
CEO and Director
Executive Director
|
7,692
+inf%
13.00
99,996
USD
|
7,692
+inf%
|
13.00
|
99,996
USD
|
|
|
2020-07-22 |
2020-07-20 |
PS
Planned sale
|
Gasmi Mehdi
Non-Executive Director
|
5,000
-1.8%
17.60
87,978
USD
|
5,000
-1.8%
|
17.60
|
87,978
USD
|
|
|
2020-06-23 |
2020-06-22 |
PS
Planned sale
|
Gasmi Mehdi
Non-Executive Director
|
23,605
-7.9%
25.06
591,617
USD
|
23,605
-7.9%
|
25.06
|
591,617
USD
|
|
|
2020-06-18 |
2020-06-18 |
PS
Planned sale
|
Gasmi Mehdi
Non-Executive Director
|
11,127
-3.9%
25.01
278,329
USD
|
11,127
-3.9%
|
25.01
|
278,329
USD
|
|
|
2020-06-18 |
2020-06-17 |
PS
Planned sale
|
Gasmi Mehdi
Non-Executive Director
|
268
-0.1%
25.01
6,703
USD
|
268
-0.1%
|
25.01
|
6,703
USD
|
|
|
2020-06-17 |
2020-06-16 |
S
Sale
|
PATTERSON LEONE D
President
Officer
|
13,171
-10.7%
24.68
325,060
USD
|
13,171
-10.7%
|
24.68
|
325,060
USD
|
|
|
2020-06-17 |
2020-06-15 |
PS
Planned sale
|
Gasmi Mehdi
Non-Executive Director
|
159
-0.1%
23.59
3,751
USD
|
159
-0.1%
|
23.59
|
3,751
USD
|
|
|
2020-06-17 |
2020-06-15 |
PS
Planned sale
|
Gasmi Mehdi
Non-Executive Director
|
3,425
-1.2%
23.00
78,787
USD
|
3,425
-1.2%
|
23.00
|
78,787
USD
|
|
|
2020-06-17 |
2020-06-15 |
PS
Planned sale
|
Gasmi Mehdi
Non-Executive Director
|
1,416
-0.5%
21.93
31,047
USD
|
1,416
-0.5%
|
21.93
|
31,047
USD
|
|
|
2020-06-17 |
2020-06-15 |
PS
Planned sale
|
Gasmi Mehdi
Non-Executive Director
|
5,000
-1.8%
21.01
105,042
USD
|
5,000
-1.8%
|
21.01
|
105,042
USD
|
|
|
2020-05-22 |
2020-05-20 |
PS
Planned sale
|
Gasmi Mehdi
Non-Executive Director
|
1,401
-0.5%
20.01
28,030
USD
|
1,401
-0.5%
|
20.01
|
28,030
USD
|
|
|
2020-05-20 |
2020-05-18 |
PS
Planned sale
|
Gasmi Mehdi
Non-Executive Director
|
300
-0.1%
19.03
5,709
USD
|
300
-0.1%
|
19.03
|
5,709
USD
|
|
|
2020-05-20 |
2020-05-18 |
PS
Planned sale
|
Gasmi Mehdi
Non-Executive Director
|
4,700
-1.7%
18.11
85,124
USD
|
4,700
-1.7%
|
18.11
|
85,124
USD
|
|
|
2020-05-20 |
2020-05-06 |
PS
Planned sale
|
Gasmi Mehdi
Non-Executive Director
|
25,000
-8.3%
20.03
500,668
USD
|
25,000
-8.3%
|
20.03
|
500,668
USD
|
|
|
2020-05-08 |
2020-05-06 |
PS
Planned sale
|
PATTERSON LEONE D
CEO, President and Director
Executive Director
|
20,000
-13.9%
20.02
400,400
USD
|
20,000
-13.9%
|
20.02
|
400,400
USD
|
|
|
2020-05-20 |
2020-05-05 |
PS
Planned sale
|
Gasmi Mehdi
Non-Executive Director
|
10,000
-3.5%
16.26
162,573
USD
|
10,000
-3.5%
|
16.26
|
162,573
USD
|
|
|
2020-03-25 |
2020-03-20 |
PS
Planned sale
|
PATTERSON LEONE D
CEO, President and Director
Executive Director
|
39,526
-24.3%
10.17
401,908
USD
|
39,526
-24.3%
|
10.17
|
401,908
USD
|
|
|
2020-03-18 |
2020-03-17 |
PS
Planned sale
|
PATTERSON LEONE D
CEO, President and Director
Executive Director
|
474
-0.3%
10.02
4,749
USD
|
474
-0.3%
|
10.02
|
4,749
USD
|
|
|
2020-02-20 |
2020-02-18 |
PS
Planned sale
|
Gasmi Mehdi
Non-Executive Director
|
5,000
-1.9%
16.23
81,156
USD
|
5,000
-1.9%
|
16.23
|
81,156
USD
|
|
|
2020-02-14 |
2020-02-14 |
B
Purchase
|
Scopa James Paul
Non-Executive Director
|
10,000
+50.0%
13.75
137,500
USD
|
10,000
+50.0%
|
13.75
|
137,500
USD
|
|
|
2020-02-14 |
2020-02-12 |
PS
Planned sale
|
Gasmi Mehdi
Non-Executive Director
|
10,000
-3.7%
15.07
150,690
USD
|
10,000
-3.7%
|
15.07
|
150,690
USD
|
|
|
2019-12-26 |
2019-12-23 |
PS
Planned sale
|
PATTERSON LEONE D
CEO, President and Director
Executive Director
|
40,000
-14.9%
10.72
428,800
USD
|
40,000
-14.9%
|
10.72
|
428,800
USD
|
|
|
2019-05-06 |
2019-05-06 |
B
Purchase
|
Scopa James Paul
Non-Executive Director
|
20,000
+inf%
6.71
134,200
USD
|
20,000
+inf%
|
6.71
|
134,200
USD
|
|
|
2015-06-17 |
2015-06-15 |
PS
Planned sale
|
Gasmi Mehdi
SVP,Pharmaceutical Development
Officer
|
500
-6.7%
39.86
19,931
USD
|
500
-6.7%
|
39.86
|
19,931
USD
|
|
|
2015-06-15 |
2015-06-12 |
PS
Planned sale
|
Bain Linda
Chief Financial Officer
Officer
|
3,500
-28.0%
39.94
139,795
USD
|
3,500
-28.0%
|
39.94
|
139,795
USD
|
|
|
2015-06-11 |
2015-06-10 |
PS
Planned sale
|
Chalberg Thomas W.
Chief Executive Officer
Executive Director
|
6,995
-2.6%
38.90
272,123
USD
|
6,995
-2.6%
|
38.90
|
272,123
USD
|
|
|
2015-06-11 |
2015-06-10 |
PS
Planned sale
|
Chalberg Thomas W.
Chief Executive Officer
Executive Director
|
12,970
-4.6%
38.04
493,339
USD
|
12,970
-4.6%
|
38.04
|
493,339
USD
|
|
|
2015-06-11 |
2015-06-10 |
PS
Planned sale
|
Blumenkranz Mark S.
Non-Executive Director
|
600
-0.1%
39.91
23,948
USD
|
600
-0.1%
|
39.91
|
23,948
USD
|
|
|
2015-06-11 |
2015-06-09 |
PS
Planned sale
|
Blumenkranz Mark S.
Non-Executive Director
|
200
-0.0%
37.35
7,470
USD
|
200
-0.0%
|
37.35
|
7,470
USD
|
|
|
2015-06-11 |
2015-06-09 |
PS
Planned sale
|
Blumenkranz Mark S.
Non-Executive Director
|
7,000
-1.3%
36.20
253,402
USD
|
7,000
-1.3%
|
36.20
|
253,402
USD
|
|
|
2015-06-10 |
2015-06-08 |
PS
Planned sale
|
Gasmi Mehdi
VP, Pharmaceutical Development
Officer
|
82
-1.2%
39.88
3,270
USD
|
82
-1.2%
|
39.88
|
3,270
USD
|
|
|
2015-06-10 |
2015-06-08 |
PS
Planned sale
|
Gasmi Mehdi
VP, Pharmaceutical Development
Officer
|
183
-2.5%
38.95
7,128
USD
|
183
-2.5%
|
38.95
|
7,128
USD
|
|
|
2015-06-10 |
2015-06-08 |
PS
Planned sale
|
Gasmi Mehdi
VP, Pharmaceutical Development
Officer
|
235
-3.1%
37.97
8,923
USD
|
235
-3.1%
|
37.97
|
8,923
USD
|
|
|
2015-06-10 |
2015-06-08 |
PS
Planned sale
|
Wachter Paul
Non-Executive Director
|
176
-0.5%
39.88
7,019
USD
|
176
-0.5%
|
39.88
|
7,019
USD
|
|
|
2015-06-10 |
2015-06-08 |
PS
Planned sale
|
Wachter Paul
Non-Executive Director
|
475
-1.2%
38.96
18,505
USD
|
475
-1.2%
|
38.96
|
18,505
USD
|
|
|
2015-06-05 |
2015-06-04 |
PS
Planned sale
|
Hull Hans
SVP, Business Operations
Officer
|
2,000
-15.0%
37.64
75,283
USD
|
2,000
-15.0%
|
37.64
|
75,283
USD
|
|
|
2015-06-02 |
2015-06-01 |
PS
Planned sale
|
Schwartz Steven Daniel
Non-Executive Director
|
3,093
-0.8%
36.81
113,854
USD
|
3,093
-0.8%
|
36.81
|
113,854
USD
|
|
|
2015-06-02 |
2015-06-01 |
PS
Planned sale
|
Wachter Paul
Non-Executive Director
|
210
-0.5%
36.81
7,730
USD
|
210
-0.5%
|
36.81
|
7,730
USD
|
|
|
2015-05-29 |
2015-05-28 |
PS
Planned sale
|
Gasmi Mehdi
VP, Pharmaceutical Development
Officer
|
500
-6.7%
38.02
19,009
USD
|
500
-6.7%
|
38.02
|
19,009
USD
|
|
|
2015-05-27 |
2015-05-26 |
PS
Planned sale
|
Wachter Paul
Non-Executive Director
|
102
-0.2%
38.30
3,906
USD
|
102
-0.2%
|
38.30
|
3,906
USD
|
|
|
2015-05-27 |
2015-05-26 |
PS
Planned sale
|
Wachter Paul
Non-Executive Director
|
304
-0.7%
37.59
11,428
USD
|
304
-0.7%
|
37.59
|
11,428
USD
|
|
